The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 355:2048-2050 November 9, 2006 Number 19
NextNext

Suppressed Bone Turnover during Alendronate Therapy for High-Turnover Osteoporosis

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
To the Editor: Bisphosphonates are the most widely used agents to prevent and treat osteoporosis.1 Although their safety has been tested in randomized trials (for up to 10 years),2 reports of previously unnoticed complications, such as severe suppression of bone turnover3 and osteonecrosis of the jaw,4 have emerged with long-term use.

A 35-year-old man was referred to our Bone Health Program in 1996 because of wrist and pelvic fractures after mild trauma. The z scores for bone mineral density (BMD) on dual-energy x-ray absorptiometry were –4.9 at the spine and –1.7 at the femoral neck. Biopsy of the right iliac . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.